fbpx

Xbrane Biopharma AB

XBRANE.ST

$0.02

Closing

▼-0.69%

1D

▲7.71%

YTD

XBRANE

BBG00BV3XZK8

Exchange

Sector

Market cap

$23.75M

Volume

9,945,017

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$23.75M

Analysts' Rating

BUY

Price Target (Mean)

0.03

Total Analysts

2

P/E

Operating Margin

-124.29%

Beta

1.89

Revenue Growth

13.45%

52 week high

$0.18

52 week low

$0.01

Div. Yield

0.00%

EPS Growth

-42.09

Company Profile

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company’s main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.